Tiger Brokers

STRATA Skin Sciences FY2025 operating loss narrows 49% to $(4.7) million; revenue falls 9% to $30.7 million

Reuters
Mar 26
STRATA Skin Sciences FY2025 operating loss narrows 49% to $(4.7) million; revenue falls 9% to $30.7 million
  • STRATA Skin Sciences published its annual report (Form 10-K) for the fiscal year ended Dec. 31, 2025, reporting net revenues of USD 30.7 million, down 9%.
  • Cost of revenues was USD 12.8 million, down 11%, and gross profit was USD 17.9 million, down 7%.
  • Loss from operations was USD 4.7 million and net loss was USD 6.3 million.
  • Dermatology recurring procedures revenue was USD 21.5 million, up 1%, while dermatology procedures equipment revenue was USD 9.2 million, down 26% due primarily to lower international equipment sales tied to tariffs and retaliatory trade practices.
  • Cash and cash equivalents and restricted cash totaled USD 7.9 million, and the company said it is in default under its MidCap senior term facility following its Nasdaq delisting, raising substantial doubt about its ability to continue as a going concern.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. STRATA Skin Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-011231), on March 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10